期刊文献+

WHO和我国基本药物目录中神经系统用药收录情况的比较研究 被引量:2

Comparative Study on the Collection of Nervous System Medicines in Essential Medicine List of WHO and China
暂未订购
导出
摘要 目的:为优化我国基本药物目录中神经系统用药品种提供参考。方法:查阅历版世界卫生组织(WHO)《基本药物示范目录》(简称WHO EML),对其中神经系统用药的收录情况进行统计分析,并将2017年版WHO EML与我国2018年版《国家基本药物目录》(简称NEML)进行比较。结果:1977-2017年,各版WHO EML中收录的神经系统用药品种数和疾病覆盖范围均变动不大。与2017年版WHO EML相比,我国2018年版NEML中神经系统用药品种更多(54种vs.30种),且覆盖了更多的疾病类型,如痴呆(石杉碱甲)、神经痛(普瑞巴林)等;但同样,对于多发性硬化症、神经痛和痴呆等疾病的治疗,可选择的药物并不多,且存在部分同类药物(作用机制相同或者相似)重复收录和部分药物不良反应严重的问题。结论:建议不断优化和完善国家基本药物目录,适当增加部分治疗神经系统疾病的品种,以提高该类疾病的治疗效果,进一步降低患者负担。 OBJECTIVE:To optimize the type of nervous system medicines in National Essential Medicine List of China.METHODS:Various editions of WHO Essential Medicine Model List(WHO EML)were consulted,the collection of nervous system medicines was analyzed statistically,and 2017 edition of WHO EML was compared with 2018 edition of National Essential Medicine List of China(NEML).RESULTS:During 1977-2017,the total number of nervous system medicines and disease coverage included in each edition of WHO EML had little change.Compared with 2017 edition of WHO EML,2018 edition of NEML contained more medicines for nervous system disease(54 medicines vs.30 medicines),and covered more disease types,such as dementia(huperzine A)and neuralgia(pregabalin),etc.However,for the treatment of multiple sclerosis,neuralgia,dementia and other diseases,there were not many medicines to choose,and some similar medicines(with the same or similar mechanism of action)were collected repeatedly and some medicines had serious adverse reaction.CONCLUSIONS:It is suggested that National Essential Medicine List should be continuously optimized and perfected,the varieties of essential medicines for the treatment of nervous system diseases should be increased appropriately,for improving the treatment effect of such diseases and reducing the cost burden of patients.
作者 左玮 孙雯娟 唐筱婉 牛子冉 张波 ZUO Wei;SUN Wenjuan;TANG Xiaowan;NIU Ziran;ZHANG Bo(Dept.of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处 《中国药房》 CAS 北大核心 2020年第4期397-401,共5页 China Pharmacy
基金 国家自然科学基金资助项目(No.81601033) 中国医学科学院医学与健康科技创新工程项目(No.2017-I2M-1-011)
关键词 基本药物 基本药物目录 神经系统疾病 世界卫生组织 中国 比较 Essential medicine Essential Medicine List Nerve system disease WHO China Comparison
  • 相关文献

参考文献8

二级参考文献308

  • 1李晓强,王深明.深静脉血栓形成的诊断和治疗指南(第二版)[J].中国血管外科杂志(电子版),2013,5(1):23-26. 被引量:189
  • 2WHO第15届“基本药物的选择与运用”专家会议于2007年3月19~23日在日内瓦召开[J].中国循证医学杂志,2007,7(4). 被引量:2
  • 3Gawel MJ,Kreeft J,Nelson RF.et al. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine.Can J Neurol Sci.1992.19: 340-345.
  • 4van de Yen LL,Franke CL,Koehler PJ. Prophylactic treatment of migraine with bisoprolol:a placebo-controlled study.Cephalalgia,1997.17:596-599.
  • 5Stellar S,Ahrens SP,Meibohm AR.et al. Migraine prevention with timolol.A double-blind crossover study.JAMA,1984.252: 2576-2580.
  • 6Johannsson V,Nilsson LR,Widelius T.et al Atenolol in migraine prophylaxis a double-blind cross-over multicentre study.Headache,1987.27:372-374.
  • 7Louis P. A double-blind placebo-controlled prophylactic study of flunarizine in migraine.Headache,1981.21:235-239.
  • 8Diamond S,Schenbaum H. Flunarizine,a calcium chaimel blocker,in the prophylactic treatment of migraine.Headache,1983.23:39-42.
  • 9Amery WK,Caers LI,Aerts TJ. Flunarizine,a calcium entry blocker in migraine prophylaxis.Headache,1985.25:249-254.
  • 10Bono G,Manzoni GC,Martucci N.et al Flunarizine in common migraine:Italian cooperative trial.II.Long-term follow-up.Cephalalgia,1985.5(Suppl2): 155-158.

共引文献225

同被引文献37

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部